drugset / Trial / NCT06555133
Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC
NaSingle-groupOpen-labelTreatment
Summary
BrUOG-430 is a prospective, single-arm, phase 2 trial evaluating yttrium-90 radioembolization in combination with capecitabine and atezolizumab for the treatment of unresectable colorectal cancer liver metastases in individuals who have been treated with two or more lines of systemic therapy.
Timeline
- Start
- 2025-04-07
- Primary completion
- 2026-09-01
- Completion
- 2029-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Capecitabine | Small molecule | 825 mg/m2 | Oral |
| Subject | Yttrium-90 | Other / unclassified | — | — |